JAK2 and cancer: To the best of our knowledge, the study shows for the first time that the selective JAK2 inhibitor, AG490 and STAT3 inhibitor, S3I-201, downregulate MCL-1, STAT3 and VEGFA and that this process is accompanied by the decreased proliferation and increased apoptosis of LNCaP cancer cells.